Lilly weight-loss pill Foundayo wins FDA approval

U.S. regulators have cleared Eli Lilly’s once-daily weight-loss pill for sale. The U.S. Food and Drug Administration (FDA) said on Wednesday it approved orforglipron, which will be marketed under the brand name Foundayo. The decision gives Lilly a new entry in the fast-growing GLP-1 category, where medicines are used for appetite suppression.

What happened: Lilly said Foundayo will begin shipping on April 6 through the company’s direct program. After that initial rollout, the company said the drug will also be available through retail pharmacies and telehealth providers. The approval sets up more direct competition with Novo Nordisk in GLP-1 medicines, including products such as Wegovy.

How the drug performed: Foundayo is an oral medication taken once per day. In clinical trials, the pill produced a 12% to 15% reduction in body weight, according to the information provided. Lilly also highlighted a practical feature: the pill can be taken without specific timing requirements related to meals or other medicines, which the company described as a convenience advantage compared with some existing treatments.

Safety labeling: The FDA-approved label for Foundayo includes a boxed warning about an increased risk of thyroid c-cell tumors. The same type of warning appears on Novo Nordisk’s oral and injectable Wegovy, according to the details provided. The inclusion of a boxed warning is a prominent labeling element that accompanies certain risks and is presented directly on the product label.

Regulatory pathway: The FDA used a fast-track approach for Foundayo under the Commissioner’s National Priority voucher program. Officials describe the program as a way to speed up decisions for drugs viewed as having significant public health impact. In this case, Lilly received the voucher as part of an agreement with the Trump administration tied to reducing the prices of its weight-loss medicines for government programs and for cash-paying patients.

What it means: The approval adds a new oral option to a market that has been dominated by high-demand GLP-1 therapies and intensifies competition between major pharmaceutical companies. The planned distribution through a direct program, followed by retail and telehealth channels, also underscores how access routes are becoming a central feature of commercialization strategies for weight-loss medicines.